Drug delivery system targeting advanced hepatocellular carcinoma: Current and future

Xue Zhang; Huei Leng Helena Ng; Aiping LYU; Congcong Lin; Limin ZHOU; Ge Lin; Yanbo Zhang; Zhijun YANG; Hong Qi ZHANG

doi:10.1016/j.nano.2015.12.381

Drug delivery system targeting advanced hepatocellular carcinoma: Current and future

Xue Zhang
, Huei Leng Helena Ng
, Aiping LYU
, Congcong Lin
, Limin ZHOU
, Ge Lin
, Yanbo Zhang
, Zhijun YANG^*
, Hong Qi ZHANG^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

111 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) has a fairly high morbidity and is notoriously difficult to treat due to long latent period before detection, multidrug resistance and severe drug-related adverse effects from chemotherapy. Targeted drug delivery systems (DDS) that can selectively deliver therapeutic drugs into tumor sites have demonstrated a great potential in cancer treatment, which could be utilized to resolve the limitations of conventional chemotherapy. Numerous preclinical studies of DDS have been published, but targeted DDS for HCC has yet to be made for practical clinical use. Since rational targeted DDS design should take cancer-specific properties into consideration, we have reviewed the biological and physicochemical properties of HCC extensively to provide a comprehensive understanding on HCC, and recent DDS studies on HCC, aiming to find some potential targeted DDSs for HCC treatment and a meaningful platform for further development of HCC treatments.

Original language	English
Pages (from-to)	853-869
Number of pages	17
Journal	Nanomedicine: Nanotechnology, Biology, and Medicine
Volume	12
Issue number	4
DOIs	https://doi.org/10.1016/j.nano.2015.12.381
Publication status	Published - May 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

User-Defined Keywords

Advanced hepatocellular carcinoma
Liver cancer
Nanomedicine
Targeted drug delivery systems

Access to Document

10.1016/j.nano.2015.12.381

Cite this

@article{f8a5dceb258f429cad09151c94fa922a,

title = "Drug delivery system targeting advanced hepatocellular carcinoma: Current and future",

abstract = "Hepatocellular carcinoma (HCC) has a fairly high morbidity and is notoriously difficult to treat due to long latent period before detection, multidrug resistance and severe drug-related adverse effects from chemotherapy. Targeted drug delivery systems (DDS) that can selectively deliver therapeutic drugs into tumor sites have demonstrated a great potential in cancer treatment, which could be utilized to resolve the limitations of conventional chemotherapy. Numerous preclinical studies of DDS have been published, but targeted DDS for HCC has yet to be made for practical clinical use. Since rational targeted DDS design should take cancer-specific properties into consideration, we have reviewed the biological and physicochemical properties of HCC extensively to provide a comprehensive understanding on HCC, and recent DDS studies on HCC, aiming to find some potential targeted DDSs for HCC treatment and a meaningful platform for further development of HCC treatments.",

keywords = "Advanced hepatocellular carcinoma, Liver cancer, Nanomedicine, Targeted drug delivery systems",

author = "Xue Zhang and Ng, \{Huei Leng Helena\} and Aiping LYU and Congcong Lin and Limin ZHOU and Ge Lin and Yanbo Zhang and Zhijun YANG and ZHANG, \{Hong Qi\}",

note = "Funding Information: We gratefully acknowledge funding for this work provided by the Hong Kong Baptist University Faculty Research Grant ( FRG2/14-15/082 ), and the University Grants Committee of Hong Kong for the General Research Fund ( HKBU 12102514 ). ",

year = "2016",

month = may,

doi = "10.1016/j.nano.2015.12.381",

language = "English",

volume = "12",

pages = "853--869",

journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",

issn = "1549-9634",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Drug delivery system targeting advanced hepatocellular carcinoma

T2 - Current and future

AU - Zhang, Xue

AU - Ng, Huei Leng Helena

AU - LYU, Aiping

AU - Lin, Congcong

AU - ZHOU, Limin

AU - Lin, Ge

AU - Zhang, Yanbo

AU - YANG, Zhijun

AU - ZHANG, Hong Qi

N1 - Funding Information: We gratefully acknowledge funding for this work provided by the Hong Kong Baptist University Faculty Research Grant ( FRG2/14-15/082 ), and the University Grants Committee of Hong Kong for the General Research Fund ( HKBU 12102514 ).

PY - 2016/5

Y1 - 2016/5

N2 - Hepatocellular carcinoma (HCC) has a fairly high morbidity and is notoriously difficult to treat due to long latent period before detection, multidrug resistance and severe drug-related adverse effects from chemotherapy. Targeted drug delivery systems (DDS) that can selectively deliver therapeutic drugs into tumor sites have demonstrated a great potential in cancer treatment, which could be utilized to resolve the limitations of conventional chemotherapy. Numerous preclinical studies of DDS have been published, but targeted DDS for HCC has yet to be made for practical clinical use. Since rational targeted DDS design should take cancer-specific properties into consideration, we have reviewed the biological and physicochemical properties of HCC extensively to provide a comprehensive understanding on HCC, and recent DDS studies on HCC, aiming to find some potential targeted DDSs for HCC treatment and a meaningful platform for further development of HCC treatments.

AB - Hepatocellular carcinoma (HCC) has a fairly high morbidity and is notoriously difficult to treat due to long latent period before detection, multidrug resistance and severe drug-related adverse effects from chemotherapy. Targeted drug delivery systems (DDS) that can selectively deliver therapeutic drugs into tumor sites have demonstrated a great potential in cancer treatment, which could be utilized to resolve the limitations of conventional chemotherapy. Numerous preclinical studies of DDS have been published, but targeted DDS for HCC has yet to be made for practical clinical use. Since rational targeted DDS design should take cancer-specific properties into consideration, we have reviewed the biological and physicochemical properties of HCC extensively to provide a comprehensive understanding on HCC, and recent DDS studies on HCC, aiming to find some potential targeted DDSs for HCC treatment and a meaningful platform for further development of HCC treatments.

KW - Advanced hepatocellular carcinoma

KW - Liver cancer

KW - Nanomedicine

KW - Targeted drug delivery systems

UR - https://www.scopus.com/pages/publications/84960897041

U2 - 10.1016/j.nano.2015.12.381

DO - 10.1016/j.nano.2015.12.381

M3 - Review article

C2 - 26772424

AN - SCOPUS:84960897041

SN - 1549-9634

VL - 12

SP - 853

EP - 869

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

IS - 4

ER -

Drug delivery system targeting advanced hepatocellular carcinoma: Current and future

Abstract

UN SDGs

User-Defined Keywords

Access to Document

Other files and links

Fingerprint

Cite this